BeiGene's innovative cancer treatments, Brukinsa and Tevimbra, are driving growth. Click for a look at ONC and its latest ...

But the mainstream media market either misrepresents the realities and nuances inherent to Cambridge, or glosses over us altogether. Too many of our stories have remained unheard, due to lack of ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.

AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry. The drug maker said it is "firmly committed to investing ...

AstraZeneca is bolstering its US manufacturing presence as President Donald Trump's White Hulls mulls the imposition of fresh tariffs on drug imports.

It does not necessarily reflect the view of The Herald. AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry.

AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry. The drug maker said it is “firmly committed to ...

"Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. "Overall, we are making excellent progress ...

China In April 2025, there are following developments in relation to the China investigations: First, in relation to the illegal drug importation allegations, AstraZeneca received an Appraisal ...